{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:25:34Z","timestamp":1772119534884,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K15529"],"award-info":[{"award-number":["21K15529"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s10549-023-07111-x","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T01:01:36Z","timestamp":1695258096000},"page":"57-71","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Eribulin promotes proliferation of CD8+ T cells and potentiates T cell-mediated anti-tumor activity against triple-negative breast cancer cells"],"prefix":"10.1007","volume":"203","author":[{"given":"Tadafumi","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8283-4989","authenticated-orcid":false,"given":"Takaaki","family":"Oba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Oshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"7111_CR1","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429\u20134434","journal-title":"Clin Cancer Res"},{"key":"7111_CR2","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1634\/theoncologist.2014-0002","volume":"19","author":"M Bonotto","year":"2014","unstructured":"Bonotto M, Gerratana L, Poletto E, Driol P, Giangreco M, Russo S, Minisini AM, Andreetta C, Mansutti M, Pisa FE, Fasola G, Puglisi F (2014) Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist 19:608\u2013615","journal-title":"Oncologist"},{"key":"7111_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10549-016-4080-9","volume":"161","author":"WD den Brok","year":"2017","unstructured":"den Brok WD, Speers CH, Gondara L, Baxter E, Tyldesley SK, Lohrisch CA (2017) Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Res Treat 161:549\u2013556","journal-title":"Breast Cancer Res Treat"},{"key":"7111_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/his.12904","volume":"69","author":"RK Beckers","year":"2016","unstructured":"Beckers RK, Selinger CI, Vilain R, Madore J, Wilmott JS, Harvey K, Holliday A, Cooper CL, Robbins E, Gillett D, Kennedy CW, Gluch L, Carmalt H, Mak C, Warrier S, Gee HE, Chan C, McLean A, Walker E, McNeil CM, Beith JM, Swarbrick A, Scolyer RA, O\u2019Toole SA (2016) Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology 69:25\u201334","journal-title":"Histopathology"},{"key":"7111_CR5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nature10933","volume":"486","author":"SP Shah","year":"2012","unstructured":"Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R, Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK, Griffith M, Moradian A, Cheng SW, Morin GB, Watson P, Gelmon K, Chia S, Chin SF, Curtis C, Rueda OM, Pharoah PD, Damaraju S, Mackey J, Hoon K, Harkins T, Tadigotla V, Sigaroudinia M, Gascard P, Tlsty T, Costello JF, Meyer IM, Eaves CJ, Wasserman WW, Jones S, Huntsman D, Hirst M, Caldas C, Marra MA, Aparicio S (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486:395\u2013399","journal-title":"Nature"},{"key":"7111_CR6","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396:1817\u20131828","journal-title":"Lancet"},{"key":"7111_CR7","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Di\u00e9ras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379:2108\u20132121","journal-title":"N Engl J Med"},{"issue":"5","key":"7111_CR8","doi-asserted-by":"publisher","first-page":"e002432","DOI":"10.1136\/jitc-2021-002432","volume":"9","author":"T Oba","year":"2021","unstructured":"Oba T, Makino K, Kajihara R, Yokoi T, Araki R, Abe M, Minderman H, Chang AE, Odunsi K, Ito F (2021) In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models. J Immunother Cancer 9(5):e002432","journal-title":"J Immunother Cancer"},{"key":"7111_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","volume":"39","author":"S Srivastava","year":"2021","unstructured":"Srivastava S, Furlan SN, Jaeger-Ruckstuhl CA, Sarvothama M, Berger C, Smythe KS, Garrison SM, Specht JM, Lee SM, Amezquita RA, Voillet V, Muhunthan V, Yechan-Gunja S, Pillai SPS, Rader C, Houghton AM, Pierce RH, Gottardo R, Maloney DG, Riddell SR (2021) Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade. Cancer Cell 39:193-208.e110","journal-title":"Cancer Cell"},{"key":"7111_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00262-012-1388-0","volume":"62","author":"G Chen","year":"2013","unstructured":"Chen G, Emens LA (2013) Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother 62:203\u2013216","journal-title":"Cancer Immunol Immunother"},{"key":"7111_CR11","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","volume":"3","author":"LA Emens","year":"2015","unstructured":"Emens LA, Middleton G (2015) The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res 3:436\u2013443","journal-title":"Cancer Immunol Res"},{"key":"7111_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3626","volume":"11","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Zitvogel L, Kroemer G (2012) The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 11:215\u2013233","journal-title":"Nat Rev Drug Discov"},{"key":"7111_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.795650","volume":"11","author":"Q Ji","year":"2021","unstructured":"Ji Q, Ding J, Hao M, Luo N, Huang J, Zhang W (2021) Immune checkpoint inhibitors combined with chemotherapy compared with chemotherapy alone for triple-negative breast cancer: a systematic review and meta-analysis. Front Oncol 11:795650","journal-title":"Front Oncol"},{"key":"7111_CR14","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","volume":"4","author":"MA Jordan","year":"2005","unstructured":"Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4:1086\u20131095","journal-title":"Mol Cancer Ther"},{"key":"7111_CR15","first-page":"1509","volume":"27","author":"J Liu","year":"2007","unstructured":"Liu J, Towle MJ, Cheng H, Saxton P, Reardon C, Wu J, Murphy EA, Kuznetsov G, Johannes CW, Tremblay MR, Zhao H, Pesant M, Fang FG, Vermeulen MW, Gallagher BM Jr, Littlefield BA (2007) In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent. Anticancer Res 27:1509\u20131518","journal-title":"Anticancer Res"},{"key":"7111_CR16","doi-asserted-by":"publisher","first-page":"5760","DOI":"10.1158\/0008-5472.CAN-04-1169","volume":"64","author":"G Kuznetsov","year":"2004","unstructured":"Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, Kishi Y, Yu MJ, Littlefield BA (2004) Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 64:5760\u20135766","journal-title":"Cancer Res"},{"key":"7111_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170634","volume":"12","author":"S Kashiwagi","year":"2017","unstructured":"Kashiwagi S, Asano Y, Goto W, Takada K, Takahashi K, Noda S, Takashima T, Onoda N, Tomita S, Ohsawa M, Hirakawa K, Ohira M (2017) Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer. PLoS ONE 12:e0170634","journal-title":"PLoS ONE"},{"key":"7111_CR18","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s12282-020-01067-2","volume":"27","author":"Y Miyoshi","year":"2020","unstructured":"Miyoshi Y, Yoshimura Y, Saito K, Muramoto K, Sugawara M, Alexis K, Nomoto K, Nakamura S, Saeki T, Watanabe J, Perez-Garcia JM, Cortes J (2020) High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician\u2019s choice-in the EMBRACE study. Breast Cancer 27:706\u2013715","journal-title":"Breast Cancer"},{"key":"7111_CR19","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12957-021-02441-w","volume":"19","author":"T Morisaki","year":"2021","unstructured":"Morisaki T, Kashiwagi S, Asano Y, Goto W, Takada K, Ishihara S, Shibutani M, Tanaka H, Hirakawa K, Ohira M (2021) Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types. World J Surg Oncol 19:324","journal-title":"World J Surg Oncol"},{"key":"7111_CR20","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s12282-021-01232-1","volume":"28","author":"M Takahashi","year":"2021","unstructured":"Takahashi M, Inoue K, Mukai H, Yamanaka T, Egawa C, Miyoshi Y, Sakata Y, Muramoto K, Ikezawa H, Matsuoka T, Tsurutani J (2021) Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan. Breast Cancer 28:945\u2013955","journal-title":"Breast Cancer"},{"key":"7111_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10549-020-05626-1","volume":"181","author":"J Watanabe","year":"2020","unstructured":"Watanabe J, Saito M, Horimoto Y, Nakamoto S (2020) A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience. Breast Cancer Res Treat 181:211\u2013220","journal-title":"Breast Cancer Res Treat"},{"key":"7111_CR22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.21873\/anticanres.14794","volume":"41","author":"T Oba","year":"2021","unstructured":"Oba T, Maeno K, Ono M, Ito T, Kanai T, Ito KI (2021) Prognostic nutritional index is superior to neutrophil-to-lymphocyte ratio as a prognostic marker in metastatic breast cancer patients treated with eribulin. Anticancer Res 41:445\u2013452","journal-title":"Anticancer Res"},{"key":"7111_CR23","doi-asserted-by":"publisher","first-page":"939","DOI":"10.21873\/anticanres.15553","volume":"42","author":"W Goto","year":"2022","unstructured":"Goto W, Kashiwagi S, Takada K, Asano Y, Morisaki T, Shibutani M, Tanaka H, Hirakawa K, Ohira M (2022) Utility of follow-up with absolute lymphocyte count in patients undergoing eribulin treatment for early detection of progressive advanced or metastatic breast cancer. Anticancer Res 42:939\u2013946","journal-title":"Anticancer Res"},{"key":"7111_CR24","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.21873\/anticanres.15095","volume":"41","author":"S Nakamoto","year":"2021","unstructured":"Nakamoto S, Ikeda M, Kubo S, Yamamoto M, Yamashita T (2021) Dynamic changes in absolute lymphocyte counts during eribulin therapy are associated with survival benefit. Anticancer Res 41:3109\u20133119","journal-title":"Anticancer Res"},{"key":"7111_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nm.4241","volume":"23","author":"L Gattinoni","year":"2017","unstructured":"Gattinoni L, Speiser DE, Lichterfeld M, Bonini C (2017) T memory stem cells in health and disease. Nat Med 23:18\u201327","journal-title":"Nat Med"},{"key":"7111_CR26","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.immuni.2007.07.010","volume":"27","author":"NS Joshi","year":"2007","unstructured":"Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, Hagman J, Gapin L, Kaech SM (2007) Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 27:281\u2013295","journal-title":"Immunity"},{"key":"7111_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1084\/jem.20071641","volume":"205","author":"S Sarkar","year":"2008","unstructured":"Sarkar S, Kalia V, Haining WN, Konieczny BT, Subramaniam S, Ahmed R (2008) Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates. J Exp Med 205:625\u2013640","journal-title":"J Exp Med"},{"key":"7111_CR28","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1158\/0008-5472.CAN-13-2564","volume":"74","author":"L Karyampudi","year":"2014","unstructured":"Karyampudi L, Lamichhane P, Scheid AD, Kalli KR, Shreeder B, Krempski JW, Behrens MD, Knutson KL (2014) Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res 74:2974\u20132985","journal-title":"Cancer Res"},{"issue":"7","key":"7111_CR29","doi-asserted-by":"publisher","first-page":"e002662","DOI":"10.1136\/jitc-2021-002662","volume":"9","author":"H Wu","year":"2021","unstructured":"Wu H, Tang X, Kim HJ, Jalali S, Pritchett JC, Villasboas JC, Novak AJ, Yang ZZ, Ansell SM (2021) Expression of KLRG1 and CD127 defines distinct CD8(+) subsets that differentially impact patient outcome in follicular lymphoma. J Immunother Cancer 9(7):e002662","journal-title":"J Immunother Cancer"},{"key":"7111_CR30","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1158\/1078-0432.CCR-17-2156","volume":"24","author":"G Mazzaschi","year":"2018","unstructured":"Mazzaschi G, Madeddu D, Falco A, Bocchialini G, Goldoni M, Sogni F, Armani G, Lagrasta CA, Lorusso B, Mangiaracina C, Vilella R, Frati C, Alfieri R, Ampollini L, Veneziani M, Silini EM, Ardizzoni A, Urbanek K, Aversa F, Quaini F, Tiseo M (2018) Low PD-1 expression in cytotoxic CD8(+) tumor-infiltrating lymphocytes confers an immune-privileged tissue microenvironment in NSCLC with a prognostic and predictive value. Clin Cancer Res 24:407\u2013419","journal-title":"Clin Cancer Res"},{"key":"7111_CR31","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","volume":"24","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhart J, Schill C, Hess C, Savic Prince S, Wiese M, Lardinois D, Ho PC, Klein C, Karanikas V, Mertz KD, Schumacher TN, Zippelius A (2018) A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med 24:994\u20131004","journal-title":"Nat Med"},{"key":"7111_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, Carmona SJ, Scarpellino L, Gfeller D, Pradervand S, Luther SA, Speiser DE, Held W (2019) Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50:195-211.e110","journal-title":"Immunity"},{"key":"7111_CR33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, Manos M, Gjini E, Kuchroo JR, Ishizuka JJ, Collier JL, Griffin GK, Maleri S, Comstock DE, Weiss SA, Brown FD, Panda A, Zimmer MD, Manguso RT, Hodi FS, Rodig SJ, Sharpe AH, Haining WN (2019) Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol 20:326\u2013336","journal-title":"Nat Immunol"},{"key":"7111_CR34","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P (2015) The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst 1:417\u2013425","journal-title":"Cell Syst"},{"key":"7111_CR35","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1038\/s41467-020-19192-z","volume":"11","author":"T Oba","year":"2020","unstructured":"Oba T, Long MD, Keler T, Marsh HC, Minderman H, Abrams SI, Liu S, Ito F (2020) Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. Nat Commun 11:5415","journal-title":"Nat Commun"},{"key":"7111_CR36","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/s41467-021-21619-0","volume":"12","author":"T Yamauchi","year":"2021","unstructured":"Yamauchi T, Hoki T, Oba T, Jain V, Chen H, Attwood K, Battaglia S, George S, Chatta G, Puzanov I, Morrison C, Odunsi K, Segal BH, Dy GK, Ernstoff MS, Ito F (2021) T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. Nat Commun 12:1402","journal-title":"Nat Commun"},{"key":"7111_CR37","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Di\u00e9ras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C (2011) Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914\u2013923","journal-title":"Lancet"},{"key":"7111_CR38","doi-asserted-by":"publisher","first-page":"22986","DOI":"10.18632\/oncotarget.25184","volume":"9","author":"T Oba","year":"2018","unstructured":"Oba T, Ito KI (2018) Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition. Oncotarget 9:22986\u201323002","journal-title":"Oncotarget"},{"key":"7111_CR39","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/bjc.2014.80","volume":"110","author":"T Yoshida","year":"2014","unstructured":"Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, Uesugi M, Agoulnik S, Taylor N, Funahashi Y, Matsui J (2014) Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer 110:1497\u20131505","journal-title":"Br J Cancer"},{"key":"7111_CR40","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/cas.12488","volume":"105","author":"Y Funahashi","year":"2014","unstructured":"Funahashi Y, Okamoto K, Adachi Y, Semba T, Uesugi M, Ozawa Y, Tohyama O, Uehara T, Kimura T, Watanabe H, Asano M, Kawano S, Tizon X, McCracken PJ, Matsui J, Aoshima K, Nomoto K, Oda Y (2014) Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci 105:1334\u20131342","journal-title":"Cancer Sci"},{"key":"7111_CR41","unstructured":"Eisai Co. Ltd. (2016) -Anticancer drug- Halaven\u00ae Injection 1mg. Medical.eisai.ip. Document. Accessed 14 March 2023"},{"issue":"7","key":"7111_CR42","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.3390\/ijms21072411","volume":"21","author":"C Hernandez","year":"2020","unstructured":"Hernandez C, Arasanz H, Chocarro L, Bocanegra A, Zuazo M, Fernandez-Hinojal G, Blanco E, Vera R, Escors D, Kochan G (2020) Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies. Int J Mol Sci 21(7):2411","journal-title":"Int J Mol Sci"},{"key":"7111_CR43","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nm.1982","volume":"15","author":"L Gattinoni","year":"2009","unstructured":"Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, Wrzesinski C, Boni A, Cassard L, Garvin LM, Paulos CM, Muranski P, Restifo NP (2009) Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med 15:808\u2013813","journal-title":"Nat Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07111-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-07111-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07111-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T22:02:39Z","timestamp":1704578559000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-07111-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["7111"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-07111-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2844939\/v1","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]},"assertion":[{"value":"21 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Medical Ethics Committee on Clinical Investigation of Shinshu University (No. 730 and No. 3819). All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all healthy donors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}